Hospira

Hospira

Type	Subsidiary
Traded as	NYSE: HSP
Founded	May 3, 2004 (spun off from Abbott Laboratories)
Headquarters	Lake Forest, Illinois, United States
Key people	F. Michael (Mike) Ball (CEO); John C. Staley, Chairman of the Board of Directors
Products	Generic acute-care and oncology injectables, integrated infusion therapy, medication management systems
Revenue	$4.1 billion (2011)
Number of employees	Approximately 16,000
Parent	Pfizer
Website	www.hospira.com

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 15,000 employees.^[1] Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals,^[2] manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.^[3] It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

Worldwide sales in 2011 were approximately $4.1 billion.^[4] Current results are now part of Pfizer's consolidated statements.

History

Hospira corporate headquarters in Lake Forest, Illinois

In January 2004, Abbott announced it was spinning off its hospital products division.^[5]

Hospira's name was picked by employee vote. The name is derived from the words hospital, spirit, inspire and the Latin word "spero," which means "hope."^[3] Hospira became an independent company on Monday, May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales. ^[6]

In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion. The deal expanded Hospira's international reach and its presence in the oncology market.^[7]

More recent acquisitions by Hospira include biotechnology business from Pliva-Croatia in 2009, the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million, announced in late 2009 and completed in 2010;^[8] Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million, in 2010;^[9] and TheraDoc, a clinical informatics company that develops hospital surveillance systems, in 2009.^[10]

In 2011, Hospira's board chose Mike Ball, formerly president of Allergan, as Hospira's new CEO. Ball became CEO in March 2011.^[11] Hospira named John Staley its non-executive chairman with the retirement of former executive chairman Christopher Begley in January 2012. Begley had announced his retirement as Hospira's chief executive in August 2010, but had remained as executive chairman.^[12]

In 2015, Pfizer signed an agreement to acquire Hospira.^[13] The roughly $17 billion acquisition was completed in September, 2015.^[14] A year later Pfizer sold the medical devices portion of Hospira to ICU Medical for roughly $900 million in cash, stock, and other consideration.^[15][16][17]

Sodium thiopental production

Sodium thiopental is an anesthetic discovered by Abbott Laboratories in the 1930s.^[18] Hospira manufactured the drug after splitting off from Abbott under the brand name Pentothal. The WHO considers it an essential drug. However, it is also used as part of the lethal injection protocol in many US states.^[19] Though Hospira has supplied these states with the drug, it has said, "we do not support the use of any of our products in capital punishment procedures."^[20]

Wikinews has related news: Final US manufacturer ceases production of lethal injection drug; executions delayed

On January 21, 2011, the company announced that it would stop producing sodium thiopental. Hospira had recently moved production of the drug from a plant in North Carolina to a plant in Liscate, Italy. However, the Italian government threatened to bar its export unless Hospira monitored the entire supply chain all the way to the end user in order to ensure it only used for medical purposes and not converted for use in executions. The Italian constitution bans the use of capital punishment. Company officials determined there was no way it could prevent sodium thiopental from being used in executions, and did not want to expose their employees to liability.^[21][22][23]

Legislation and litigation

Oxaliplatin: In August 2009, Hospira introduced a generic version of Sanofi-Aventis SA's (SNY) colon-cancer drug known generically as oxaliplatin and by the brand name Eloxatin, in the United States. In April 2010, Hospira announced a legal settlement with Sanofi-Aventis. Under the settlement terms, Hospira agreed to stop selling oxaliplatin injection in the United States by June 30, 2010, and can relaunch the product in the United States on Aug. 9, 2012.^[24]

Biosimilars: In 2010, the U.S. Congress passed legislation that would allow the marketing of biosimilar drugs in the United States. The legislation would allow 12 years of data exclusivity for brand-name biologics. Some consumer groups, like AARP, oppose this provision, saying it would cause lack of access to the promise of such drugs.^[25]

Competitors

Hospira's competitors in specialty injectable pharmaceuticals include Fresenius AG, Baxter International Inc., Bedford Laboratories, Mylan, Sandoz, Teva Pharmaceuticals as well as divisions of several multinational pharmaceutical companies. Its competitors in medication management systems include Baxter, B. Braun Melsungen AG, CareFusion and Fresenius Medical Care AG.^[26]

Infusion pump system firmware vulnerability disclosures

In 2014-2015 two security researchers independently identified what were described as severe defects in Hospira's PCA system firmware, the software controlling various of their drug infusion equipment (CVE-2015-3459^[27] and further advisory ICSA-15-125-01B^[28]). Numerous remote exploit vulnerabilities were found, in what was believed to be the first FDA safety advisory of its kind.^[29] This was followed in July 2015 by a second FDA recommendation that hospitals discontinue use of the affected pumps entirely.^[30] The devices, extent of their flaws, and implications, were widely discussed.^[31][32][33]

References

External links

• Official website